急性冠脉综合征后外周动脉疾病与静脉血栓栓塞事件:脂蛋白(a)的作用及阿利西尤单抗的修饰效应
该研究为ODYSSEY OUTCOMES随机临床试验的预设分析,纳入18 924例近期急性冠脉综合征且接受强化或最大耐受他汀治疗的患者,随机接受PCSK9抑制剂阿利西尤单抗或安慰剂。结果显示,阿利西尤单抗降低外周动脉疾病事件风险(HR 0.69),且该效应与基线脂蛋白(a)四分位相关;静脉血栓栓塞事件风险有降低趋势但未达统计学显著性(HR 0.67)。
要点
- 阿利西尤单抗降低急性冠脉综合征后外周动脉疾病事件风险(HR 0.69)。
- 外周动脉疾病事件风险与基线脂蛋白(a)水平相关,阿利西尤单抗的获益在高脂蛋白(a)患者中更明显。
- 静脉血栓栓塞事件风险有降低趋势但未达统计学显著性(HR 0.67,P=0.06)。
核心结论
- 在接受他汀治疗的近期急性冠脉综合征患者中,外周动脉疾病事件风险与脂蛋白(a)水平相关,阿利西尤单抗可降低该风险,尤其在脂蛋白(a)较高者中。
- 静脉血栓栓塞风险是否与脂蛋白(a)水平及其降低相关尚需进一步研究确认。
研究设计与样本
- ODYSSEY OUTCOMES随机临床试验的预设分析,共纳入18 924例近期急性冠脉综合征且接受强化或最大耐受他汀治疗的患者,随机分配至阿利西尤单抗或安慰剂组。
主要发现
- 基线脂蛋白(a)中位数为21 mg/dL,校正脂蛋白(a)胆固醇后的LDL-C(LDL-Ccorrected)中位数为75 mg/dL;阿利西尤单抗治疗下中位相对降幅分别为23.5%和70.6%。
- 外周动脉疾病事件和静脉血栓栓塞事件分别发生246例和92例。
- 安慰剂组中外周动脉疾病事件风险与基线脂蛋白(a)四分位相关(Ptrend=0.0021),与基线LDL-Ccorrected四分位有相关趋势(Ptrend=0.06);静脉血栓栓塞事件与基线脂蛋白(a)四分位有相关趋势(Ptrend=0.06),与LDL-Ccorrected无关(Ptrend=0.85)。
- 阿利西尤单抗降低外周动脉疾病事件风险(HR 0.69,95%CI 0.54-0.89;P=0.004),静脉血栓栓塞事件有减少趋势但未达显著性(HR 0.67,95%CI 0.44-1.01;P=0.06)。
- 阿利西尤单抗对外周动脉疾病事件的降低与基线脂蛋白(a)四分位相关(Ptrend=0.03),与LDL-Ccorrected四分位无关(Ptrend=0.50);阿利西尤单抗治疗下,基线至第4个月脂蛋白(a)的变化(而非LDL-Ccorrected的变化)与静脉血栓栓塞事件及静脉血栓栓塞复合外周动脉疾病事件风险相关。
临床怎么用
- 对于近期急性冠脉综合征且接受他汀治疗的患者,尤其是脂蛋白(a)水平较高者,可考虑使用阿利西尤单抗以降低外周动脉疾病事件风险。
- 阿利西尤单抗对静脉血栓栓塞风险的影响尚不明确,需个体化评估。
局限性
- 静脉血栓栓塞事件数量较少(92例),阿利西尤单抗对其影响未达统计学显著性。
- 脂蛋白(a)与静脉血栓栓塞风险的关联仅为趋势性,需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with acute coronary syndrome are at risk for peripheral artery disease (PAD) events and venous thromboembolism (VTE). PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C) levels. Our objective was to ascertain whether PCSK9 inhibition reduces the risk of PAD events or VTE after acute coronary syndrome, and if such effects are related to levels of lipoprotein(a) or LDL-C. METHODS: This was a prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome), which was conducted in 18 924 patients with recent acute coronary syndrome on intensive or maximum-tolerated statin treatment who were randomized to the PCSK9 inhibitor alirocumab or placebo. In a prespecified analysis, PAD events (critical limb ischemia, limb revascularization, or amputation for ischemia) and VTE (deep vein thrombosis or pulmonary embolism) were assessed. LDL-C was corrected (LDL-Ccorrected) for cholesterol content in lipoprotein(a). RESULTS: At baseline, median lipoprotein(a) and LDL-Ccorrected were 21 and 75 mg/dL, respectively; with alirocumab, median relative reductions were 23.5% and 70.6%, respectively. PAD events and VTE occurred in 246 and 92 patients, respectively. In the placebo group, risk of PAD events was related to baseline quartile of lipoprotein(a) (Ptrend=0.0021), and tended to associate with baseline quartile of LDL-Ccorrected (Ptrend=0.06); VTE tended to associate with baseline quartile of lipoprotein(a) (Ptrend=0.06), but not LDL-Ccorrected (Ptrend=0.85). Alirocumab reduced risk of PAD events (hazard ratio [HR], 0.69 [95% CI, 0.54-0.89]; P=0.004), with nonsignificantly fewer VTE events (HR, 0.67 [95% CI, 0.44-1.01]; P=0.06). Reduction in PAD events with alirocumab was associated with baseline quartile of lipoprotein(a) (Ptrend=0.03), but not LDL-Ccorrected (Ptrend=0.50). With alirocumab, the change from baseline to Month 4 in lipoprotein(a), but not LDL-Ccorrected, was associated with the risk of VTE and the composite of VTE and PAD events. CONCLUSIONS: In statin-treated patients with recent acute coronary syndrome, risk of PAD events is related to lipoprotein(a) level and is reduced by alirocumab, particularly among those with high lipoprotein(a). Further study is required to confirm whether risk of VTE is related to lipoprotein(a) level and its reduction with alirocumab. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01663402.
引用
- Schwartz GG, Steg PG, Szarek M, et al. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation. 2020. PMID: 32223446. doi:10.1161/CIRCULATIONAHA.120.046524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。